Zai Lab Limited Stock Price, News & Analysis

Zai Lab's Phase 2 FIGHT trial for bemarituzumab shows positive results in treating FGFR2b+ gastric cancer. Key endpoints achieved statistical significance: median progression-free survival rose from 7.4 to 9.5 months, overall survival improved significantly, and overall response rate increased by 13%. The trial included 155 patients and targeted a crucial biomarker in HER2- gastric cancers. Bemarituzumab, a first-in-class therapy, could expand treatment options for cancers with FGFR2b overexpression, currently affecting about 30% of gastric cancer cases globally.

Zai Lab Limited (NASDAQ: ZLAB) announced the initiation of patient dosing in China for the global POD1UM-101 study, assessing retifanlimab for previously treated, microsatellite instability-high endometrial cancer. This study aims to enroll around 100 patients and primarily evaluates the overall response rate. Endometrial cancer, prevalent in China, has a significant unmet medical need, particularly for patients with high microsatellite instability. Retifanlimab is an investigational anti-PD1 antibody also being assessed for other cancers, with Orphan Drug Designation granted for anal cancer.

On October 28, 2020, Zai Lab announced its participation in several virtual investor conferences in November. Key events include the Citi China Investor Conference on November 5, the BioCentury 7th China Healthcare Summit and Nomura Investment Forum on November 12, and the Goldman Sachs Asia Pacific Healthcare Forum on November 17, followed by the Jefferies Virtual London Healthcare Conference on November 18. A live webcast of the Jefferies conference will be available for 90 days post-event. Zai Lab aims to deliver transformative medicines for various diseases.

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) has fully exercised its over-allotment option, resulting in the issuance of 1,584,600 additional shares. This represents 15% of the total number of Offer Shares available under the recent Global Offering. The shares will be priced at HK$562 each, generating approximately HK$890.55 million in gross proceeds. The Hong Kong Stock Exchange has approved the listing of these shares, scheduled to commence on October 16, 2020. Zai Lab aims to utilize the proceeds for purposes outlined in its Prospectus.

Zai Lab announced the dosing of the first patient in Greater China for the global MAHOGANY study, evaluating margetuximab in combination with a checkpoint inhibitor for HER2-positive gastric cancer and gastroesophageal junction cancer. This Phase 2/3 trial aims to assess margetuximab’s efficacy with or without chemotherapy. Gastric cancer is prevalent, with significant unmet medical needs. Zai Lab collaborates with MacroGenics for this study, which is crucial for addressing advanced stage cancers in China, where the prognosis is often poor.

Zai Lab Limited (NASDAQ: ZLAB) has initiated dosing of the first patient in China for the global Phase 3 POD1UM-304 study, evaluating retifanlimab alongside platinum-based chemotherapy for first-line metastatic non-small-cell lung cancer (NSCLC). The trial aims to enroll approximately 530 patients and focuses on overall survival and progression-free survival as primary endpoints. The collaboration with Incyte aims to address the significant unmet medical need for NSCLC treatment in China, where lung cancer is the leading cause of cancer deaths.

On September 28, 2020, Zai Lab announced its secondary listing on the Hong Kong Stock Exchange (stock code: 9688), successfully closing an offering of 10,564,050 new ordinary shares at HK$562.00 per share, equating to approximately US$72.52 per American depositary share. The gross proceeds from this offering are around HK$5.94 billion before costs. The international underwriters have an over-allotment option for an additional 1,584,600 shares. Zai Lab aims to enhance its presence in the rapidly growing Chinese pharmaceutical market.

Zai Lab Limited (NASDAQ: ZLAB) has successfully completed its secondary listing on the Hong Kong Stock Exchange under stock code '9688'. The listing involved the offering of 10,564,050 new ordinary shares at HK$562.00 per share, translating to approximately US$72.52 per American depositary share. The offering raised approximately HK$5.94 billion in gross proceeds. J.P. Morgan, Goldman Sachs, and Citigroup acted as joint sponsors and bookrunners for the listing. This strategic move aims to enhance Zai Lab’s presence in the fast-growing Asian market.

Zai Lab (SEHK:9688, NASDAQ:ZLAB), a biopharmaceutical company, has officially listed on the Main Board of The Stock Exchange of Hong Kong Limited as of September 27, 2020. The stock opened at HK$613.5, reflecting a 9.16% increase and a market capitalization of HK$52.724 billion. Founded in 2014 with Qiming Venture Partners as its earliest investor, Zai Lab focuses on innovative treatments for cancer, infectious, and autoimmune diseases. The company has a robust pipeline of 16 products, including two already commercialized in Greater China.